Educational guide
PerkinElmer Buys GE’s Catalog Radiochemicals, SPA Reagents, and Cytostar-T Plate Assets
Technologies pad offerings for detection and screening of new drugs, radiolabeling, and bead-based assays. PerkinElmer has purchased the assets of GE Healthcare’s 3H and 14C Catalog Radiochemicals, Scintillation Proximity Assay (SPA) reagents, and Cytostar-T p
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Technologies pad offerings for detection and screening of new drugs, radiolabeling, and bead-based assays.
PerkinElmer has purchased the assets of GE Healthcare’s 3H and 14C Catalog Radiochemicals, Scintillation Proximity Assay (SPA) reagents, and Cytostar-T plate product lines.
The Catalog Radiochemical products are used for a variety of research applications including screening of potential drug candidates through binding assays. The SPA bead-based, light-emitting assay and Cytostar-T plate technologies enable the automation of high-throughput screening (HTS) processes.
“We expect that the incorporation of these technologies will strengthen our industry-leading GPCR and kinase research product lines and complement our HTS and research reagent solutions,” says Richard M. Eglen, Ph.D., president, Bio-discovery, PerkinElmer.
PerkinElmer plans to continue expanding its NEN® radiochemical portfolio. The company’s solutions in radiometric detection include lines of readers, nuclear counters, and other instrumentation.